Corvus Pharmaceuticals (CRVS) PT Raised to $42 at Jefferies

January 22, 2026 12:22 PM EST Send to a Friend
Jefferies analyst Roger Song raised the price target on Corvus Pharmaceuticals (NASDAQ: CRVS) to $42.00 (from $13.00) while maintaining a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login